Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +7.00p +0.52% 1,346.50p 1,342.00p 1,344.50p 1,375.00p 1,320.50p 1,346.00p 368,709 16:35:22
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 1,433.4 -546.4 -260.1 - 3,267.67

Hikma Pharmaceuticals Plc AGM Results

18/05/2018 1:01pm

UK Regulatory (RNS & others)


Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart

1 Month : From Apr 2018 to May 2018

Click Here for more Hikma Pharmaceuticals Charts.

TIDMHIK

RNS Number : 6033O

Hikma Pharmaceuticals Plc

18 May 2018

Hikma Pharmaceuticals PLC

Voting Results of 2018 Annual General Meeting

LONDON, 18 May 2018 - Hikma Pharmaceuticals PLC (the "Company") announces its Annual General Meeting ("AGM"), held at Sofitel St James, 6 Waterloo Place, London SW1Y 4AN on 18 May 2018 commenced at 10:00 am. All resolutions were duly passed by shareholders by way of a poll. Resolutions 1 to 17 were passed as ordinary resolutions and Resolutions 18 to 21 were passed as special resolutions.

As previously announced, Dr. Ronald Goode retired from the Board at the close of the AGM.

Copies of the resolutions dealing with special business passed at the AGM have been submitted to the National Storage Mechanism and will shortly be available for inspection at www.morningstar.co.uk/uk/nsm

The total number of votes cast on the poll for each resolution (the full text of the resolutions is detailed in the notice of the AGM dated 28 March 2018) is set out below. The number of Ordinary Shares in issue on 18 May 2018 was 240,940,604.

 
        Resolution             Votes        %        Votes        %        Total      Withheld 
                                For                  Against                Cast 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 1. To receive 
  the 2017 report 
  and accounts              196,394,230   99.96      72,200     0.04    196,466,430    245,708 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 2. To approve 
  a final dividend 
  of 23 cents 
  per share                 196,485,553   99.89     225,796     0.11    196,711,349      788 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 3. To re-appoint 
  PricewaterhouseCoopers 
  LLP as auditors           196,099,742   99.69     610,679     0.31    196,710,421     1,717 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 4.To authorise 
  the Audit Committee 
  to determine 
  the auditors' 
  remuneration              196,703,625   100.00     5,721      0.00    196,709,346     2,792 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 5. To elect 
  Siggi Olafsson 
  as a director             195,815,999   99.55     894,642     0.45    196,710,641     1,497 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 6. To re-elect 
  Said Darwazah 
  as a director             190,417,700   96.80    6,298,814    3.20    196,716,514     1,622 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 7. To re-elect 
  Mazen Darwazah 
  as a director             193,925,828   98.58    2,783,900    1.42    196,709,728     2,410 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 8. To re-elect 
  Robert Pickering 
  as a director             190,879,517   98.02    3,848,509    1.98    194,728,026   1,984,111 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 9.To re-elect 
  Ali Al-Husry 
  as a director             195,245,623   99.26    1,464,293    0.74    196,709,916     2,222 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 10. To re-elect 
  Patrick Butler 
  as a director             193,317,043   98.28    3,393,072    1.72    196,710,115     2,022 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 11. To re-elect 
  Dr. Jochen 
  Gann as a director        195,107,616   99.19    1,602,499    0.81    196,710,115     2,022 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 12. To re-elect 
  John Castellani 
  as a director             193,529,031   98.38    3,180,885    1.62    196,709,916     2,222 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 13. To re-elect 
  Dr. Pamela 
  Kirby as a 
  director                  190,289,183   96.74    6,421,682    3.26    196,710,865     1,272 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 14. To re-elect 
  Nina Henderson 
  as a director             192,848,157   98.04    3,862,508    1.96    196,710,665     1,472 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 15. To approve 
  the remuneration 
  report for 
  the year ended 
  31 December 
  2017                      169,750,519   86.36    26,815,358   13.64   196,565,877    146,261 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 16. To approve 
  and adopt the 
  2018 Management 
  Incentive Plan            195,620,834   99.45    1,088,481    0.55    196,709,315     2,822 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 17. Authority 
  to allot shares           166,598,638   84.69    30,112,333   15.31   196,710,971     1,167 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 18. To dis-apply 
  pre-emption 
  rights for 
  general purposes          196,660,802   99.97      50,469     0.03    196,711,271      867 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 19. To dis-apply 
  pre-emption 
  rights for 
  an acquisition 
  or other capital 
  investment                195,530,359   99.40    1,179,711    0.60    196,710,070     2,067 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 20. To authorise 
  the Company 
  to purchase 
  its own shares            195,989,881   99.68     621,703     0.32    196,611,584    100,553 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 21. To authorise 
  the Company 
  to hold general 
  meetings on 
  no less than 
  14 clear days' 
  notice                    187,831,722   95.49    8,878,028    4.51    196,709,750     2,388 
-------------------------  ------------  -------  -----------  ------  ------------  ---------- 
 

Declaration of final dividend

The dividend of 23 cents per share will be paid on 24 May 2018 to shareholders on the register on 6 April 2018. Shareholders who are not resident in Jordan have been given the option of receiving their dividend in Pounds Sterling. The exchange rate in respect of this dividend will be $1.3521 to GBP1. The exchange rate for Jordanian Dinar is fixed to the US Dollar at circa 1JD to $1.41.

- ENDS -

Enquiries:

 
 Hikma Pharmaceuticals PLC 
 Peter Speirs 
  Company Secretary                +44 20 7399 2670 
 Susan Ringdal 
  VP for Investor Relations and 
  Strategy                         +44 20 7399 2670 
 

About Hikma

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit www.hikma.com.

LEI: 549300BNS685UXH4JI75

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGUWRURWRAVAAR

(END) Dow Jones Newswires

May 18, 2018 08:01 ET (12:01 GMT)

1 Year Hikma Pharmaceuticals Chart

1 Year Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart

1 Month Hikma Pharmaceuticals Chart
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V:gb D:20180526 08:26:18